News | August 08, 2022
Valiant Organics to start production of OAP and Pharma Intermediates
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
The company has reported total income of Rs. 253.42 crores during the period ended June 30, 2022.
Lupin is the 6th largest company in the Indian Pharmaceutical Market
The WAVEsystem with the WAVEcontrol 4.0 embedded
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
